SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 1,760.38 |
| Enterprise Value ($M) | 988.64 |
| Book Value ($M) | 757.50 |
| Book Value / Share | 6.90 |
| Price / Book | 2.32 |
| NCAV ($M) | 756.29 |
| NCAV / Share | 6.89 |
| Price / NCAV | 2.33 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.32 |
| Return on Assets (ROA) | -0.49 |
| Return on Equity (ROE) | -0.59 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 8.08 |
| Current Ratio | 8.08 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 863.41 |
| Assets | 864.62 |
| Liabilities | 107.12 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 45.56 |
| Operating Income | -176.29 |
| Net Income | -241.60 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -158.56 |
| Cash from Investing | -62.85 |
| Cash from Financing | 659.51 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Ra Capital Management, L.p. | 9.90 | 19.57 | |
| 13G/A | Viking Global Investors Lp | 6.50 | -13.04 | |
| 13D/A | Frazier Life Sciences X, L.P. | 15.30 | 29.96 | |
| 13D/A | Forbion Capital Fund IV Cooperatief U.A. | 10.40 | -5.90 | |
| 13D/A | BCLS II Investco, LP | 9.99 | 99.38 | |
| 13G/A | Amgen Inc |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 86,347 | 235,781 | 36.62 | |
| 67,271 | 250,815 | 26.82 | |
| 249,488 | 648,553 | 38.47 | |
| 232,833 | 896,183 | 25.98 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| MRUS – Merus N.V. | MURA – Mural Oncology plc |
| NAII – Natural Alternatives International, Inc. | NEUP – Neuphoria Therapeutics Inc. |
| NGNE – Neurogene Inc. |
Financial data and stock pages provided by
Fintel.io